NCT05988463View on ClinicalTrials.gov

Open-Label Dose-Escalation Treatment Study of Patients with IPF

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Artesunate Oral Product

Artesunate capsules administered orally twice daily beginning at 10 mg for 4 weeks, followed by 20 mg for 4 weeks, and then 30 mg for 4 weeks.

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
lead

Joseph C. Wu

OTHER